Carlo Farina overview
Carlo Farina got its doctorate in industrial chemistry in 1972 from the University of Milan and began his career as a medicinal chemist at ISF SpA in Trezzano (Milan) in 1974.
His job entailed the design and synthesis of new biologically active molecules in the gastrointestinal and central nervous systems and actively contributed to the successful synthesis, characterization and commercialization of two drugs, namely the antiulcer trithiozine (Tresanil®) and the cognition enhancer oxiracetam (Neuromet®). In 1981 he was named head of a Medicinal Chemistry laboratories, and in 1987 he was promoted to Head of Chemistry, managing drug discovery and pilot & production plants for industrial manufacturing.
In 1991, following the acquisition of ISF by SmithKline Beecham (SB), Carlo was appointed Programme Director, Bone Diseases Programme, still maintaining the responsibility for all chemical activities in Italy. In this period, the innovative research on inhibitors of osteoclast vacuolar proton ATPase allowed him gain a world-wide reputation as a V-ATPase expert, as demonstrated by several invited reviews in primary journals. In 1997 Carlo took over responsibility for the whole SB Discovery group in Italy and the SB Medicinal Chemistry group in Rennes, France. Following the merger of SmithKline Beecham with Glaxo Wellcome in 2001, Carlo became the founder and CEO of NiKem Research, a chemical technology spin-off of GlaxoSmithKline, providing products and services of medicinal chemistry to the pharmaceutical and biotechnology industry. NIKEM grew rapidly from 24 initial staff to 90, reaching an annual sales revenues of 10 millions Euro and establishing a world wide reputation as a quality Drug Discovery service provider. In 2007 Carlo left Nikem to become CEO of Brane Discovery, a spin-off of NiKem Research dedicated to the development of proprietary research approaches to neuropathic pain. Following the sale of the neuropathic pain project to Neurotune AG and the liquidation of Brane Discovery, Carlo joined Neurotune with the task of managing all medicinal and synthetic chemistry activities and the chemical and preclinical development of Neurotune compounds. With the outlicensing of the neuropathic pain franchise to Metys Pharmaceuticals, Carlo joined Metys as a consultant responsible for chemical, IP and preclinical development of its neuropathic pain products.
Carlo has authored about one hundred scientific papers, oral communications and poster presentations. He is also the inventor of about fifty patents and patent applications and is a reviewer of the Journal of Medicinal Chemistry and Bioorganic & Medicinal Chemistry Letters.